AR035786A2 - Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen - Google Patents
Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienenInfo
- Publication number
- AR035786A2 AR035786A2 ARP020101003A ARP020101003A AR035786A2 AR 035786 A2 AR035786 A2 AR 035786A2 AR P020101003 A ARP020101003 A AR P020101003A AR P020101003 A ARP020101003 A AR P020101003A AR 035786 A2 AR035786 A2 AR 035786A2
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- vitamin
- gla domain
- protein
- modified gla
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title abstract 9
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 10
- 229920001184 polypeptide Polymers 0.000 abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 9
- 101800004937 Protein C Proteins 0.000 abstract 8
- 101800001700 Saposin-D Proteins 0.000 abstract 8
- 102400000827 Saposin-D Human genes 0.000 abstract 8
- 229930003448 Vitamin K Natural products 0.000 abstract 8
- 150000001413 amino acids Chemical class 0.000 abstract 8
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 abstract 8
- 229960000856 protein c Drugs 0.000 abstract 8
- 235000019168 vitamin K Nutrition 0.000 abstract 8
- 239000011712 vitamin K Substances 0.000 abstract 8
- 150000003721 vitamin K derivatives Chemical class 0.000 abstract 8
- 229940046010 vitamin k Drugs 0.000 abstract 8
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 2
- 108010023321 Factor VII Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 229940012413 factor vii Drugs 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 108010048049 Factor IXa Proteins 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 230000035602 clotting Effects 0.000 abstract 1
- 230000009852 coagulant defect Effects 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Se describen: polipéptidos dependientes de vitamina K que incluye un dominio GLA modificado que aumenta la afinidad de unión del polipéptido con las membranas con respecto al correspondiente polipéptido nativo dependiente de vitamina K. El dominio GLA modificado puede incluir por lo menos una sustitución de amino ácido. Por ejemplo, la sustitución de amino ácido puede ser en el amino ácido 11, 12, 29, 33 o 34. El dominio GLA modificado, puede incluir una secuencia de amino ácidos que, en el estado saturado de calcio, forma una estructura terciaria que tiene un núcleo catiónico con un halo de carga electro-negativa. El polipéptido dependiente de vitamina K, puede ser por ejemplo, proteína C, proteína C actividad, factor IX, factor IXa, factor VII, factor VIIa o factor VIIa de sitio activo modificado. El dominio GLA modificado de la proteína C o la proteína C activada puede incluir un residuo ácido glutámico en el amino ácido 33 y un residuo ácido aspártico en el amino ácido 34. El dominio GLA modificado de la proteína C o de la proteína C activada, puede también incluir un residuo glutamina o ácido glutámico en el amino ácido 11. Adicionalmente, un residuo glicina puede ser sustituido en el amino ácido 12 en el dominio GLA de la proteína C o de la proteína C activada. El dominio GLA modificado del factor VII, el factor VIIa y el factor VIIa de sitio activo modificado puede contener una sustitución en el amino ácido 11 y 33. Por ejemplo, un residuo glutamina en el amino ácido 11 y un residuo ácido glutámico en el amino ácido 33, pueden estar sustituidos. Un ácido nucleico aislado que codifica una polipéptido dependiente de vitamina K que contiene un dominio GLA modificado tal como se describe arriba. Además, la presente se refiere también a una célula hospedante de mamífero que incluye un vector ácido nucleico que codifica un polipéptido dependiente de vitamina K que contiene un dominio GLA modificado según se describe arriba. Una composición farmacéutica que incluye un vehículo farmacéuticamente aceptable y una cantidad de un polipéptido dependiente de vitamina K efectiva para inhibir o incrementar la formación de coágulos en un mamífero, donde el polipéptido dependiente de vitamina K incluye un dominio GLA modificado como se ha descripto anteriormente. Un polipéptido dependiente de la vitamina K para ser utilizado en el tratamiento de una trastorno relacionado con la coagulación o en la manufactura de un medicamento para el tratamiento de un trastorno de coagulación. Métodos para incrementar o disminuir la formación de coágulos en un mamífero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/955,636 US6017882A (en) | 1997-10-23 | 1997-10-23 | Modified vitamin K-dependent polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035786A2 true AR035786A2 (es) | 2004-07-14 |
Family
ID=25497114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105278A AR020048A1 (es) | 1997-10-23 | 1998-10-22 | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. |
| ARP020101003A AR035786A2 (es) | 1997-10-23 | 2002-03-20 | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105278A AR020048A1 (es) | 1997-10-23 | 1998-10-22 | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6017882A (es) |
| EP (2) | EP1676919B1 (es) |
| JP (1) | JP4276379B2 (es) |
| KR (1) | KR20010031370A (es) |
| CN (1) | CN1246462C (es) |
| AP (1) | AP2000001811A0 (es) |
| AR (2) | AR020048A1 (es) |
| AT (1) | ATE390486T1 (es) |
| AU (1) | AU749279C (es) |
| BR (1) | BR9814611A (es) |
| CA (1) | CA2307175C (es) |
| DE (1) | DE69839313T2 (es) |
| DK (1) | DK1090128T3 (es) |
| EA (1) | EA200000449A1 (es) |
| ES (2) | ES2496104T3 (es) |
| HR (1) | HRP20000234A2 (es) |
| HU (1) | HU225993B1 (es) |
| ID (1) | ID26330A (es) |
| IL (1) | IL135603A0 (es) |
| IS (1) | IS5449A (es) |
| MY (1) | MY136336A (es) |
| NO (1) | NO20002025L (es) |
| NZ (1) | NZ504114A (es) |
| PL (1) | PL194194B1 (es) |
| PT (1) | PT1090128E (es) |
| SG (1) | SG105547A1 (es) |
| TR (1) | TR200001105T2 (es) |
| TW (1) | TW587081B (es) |
| WO (1) | WO1999020767A1 (es) |
| ZA (1) | ZA989597B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6998122B1 (en) | 1999-04-30 | 2006-02-14 | Eli Lilly And Company | Protein C derivatives |
| EP1237917A2 (en) * | 1999-11-19 | 2002-09-11 | Eli Lilly And Company | Protein c derivatives |
| ES2234807T3 (es) | 2000-02-02 | 2005-07-01 | Eli Lilly And Company | Derivados de proteina c. |
| AU2001232799A1 (en) | 2000-02-11 | 2001-08-20 | Eli Lilly And Company | Protein c derivatives |
| DE60138364D1 (de) * | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| US7812132B2 (en) * | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| AU2001278336B2 (en) * | 2000-07-31 | 2007-01-18 | Ottawa Heart Institute Research Corporation | Charged phospholipid compositions and methods for their use |
| US6933367B2 (en) | 2000-10-18 | 2005-08-23 | Maxygen Aps | Protein C or activated protein C-like molecules |
| EP1370649A1 (en) * | 2001-03-02 | 2003-12-17 | T.A.C. Thrombosis and Coagulation AB | Protein c variants |
| US20050176083A1 (en) * | 2002-03-01 | 2005-08-11 | Bjorn Dahlback | Recombinant protein c variants |
| US20030186862A1 (en) * | 2002-04-02 | 2003-10-02 | Nelsestuen Gary L. | Factor VIIa compositions |
| CN101942019A (zh) * | 2002-04-30 | 2011-01-12 | 拜耳医药保健有限公司 | 凝血因子VII或VIIa多肽变体 |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| AU2003240438A1 (en) | 2002-06-21 | 2004-01-06 | Novo Nordisk A/S | Stabilised solid compositions of factor vii polypeptides |
| US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
| EP1611236A1 (en) | 2003-03-18 | 2006-01-04 | Novo Nordisk Health Care AG | Method for the production of gla-residue containing serine proteases |
| JP4847856B2 (ja) * | 2003-03-20 | 2011-12-28 | バイエル ヘルスケア エルエルシー | ＦＶＩＩおよびＦＶＩＩａの変種 |
| EP1644504B8 (en) | 2003-06-19 | 2010-06-02 | Bayer HealthCare LLC | Factor vii or viia gla domain variants |
| CN1863908B (zh) | 2003-09-09 | 2010-08-04 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| KR100755967B1 (ko) * | 2003-10-23 | 2007-09-06 | 한국타이어 주식회사 | 타이어의 비드와 휠의 갭 측정장치 |
| AU2004294403A1 (en) | 2003-12-01 | 2005-06-16 | Novo Nordisk Health Care Ag | Nanofiltration of factor VII solutions to remove virus |
| KR20130026498A (ko) | 2003-12-19 | 2013-03-13 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물 |
| RU2385879C2 (ru) | 2004-01-21 | 2010-04-10 | Ново Нордиск Хелс Кеа Аг | Способ конъюгации пептидов, опосредованной трансглутаминазой |
| AU2005318106B2 (en) | 2004-12-23 | 2011-11-03 | Novo Nordisk Health Care Ag | Reduction of the content of protein contaminants in compositions comprising a Vitamin K-dependent protein of interest |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| EP1893230A2 (en) * | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| EP1904528B1 (en) | 2005-07-13 | 2012-10-31 | Novo Nordisk Health Care AG | Host cell protein knock-out cells for production of therapeutic proteins |
| WO2007026021A1 (en) | 2005-09-01 | 2007-03-08 | Novo Nordisk Health Care Ag | Hydrophobic interaction chromatography purification of factor vii polypeptides |
| US20090055942A1 (en) | 2005-09-14 | 2009-02-26 | Novo Nordisk Healthcare A/G | Human Coagulation Factor VII Polypeptides |
| JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
| CA2673260A1 (en) * | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
| NZ579985A (en) | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| PT2574677T (pt) | 2007-12-27 | 2017-10-19 | Baxalta Inc | Processos para cultura de células |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| TWI626057B (zh) | 2009-06-09 | 2018-06-11 | 普龍製藥有限責任公司 | 血紅素組成物 |
| WO2011074578A1 (ja) * | 2009-12-14 | 2011-06-23 | 国立大学法人北海道大学 | 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体 |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| BR112015001628A2 (pt) | 2012-07-25 | 2017-11-07 | Catalyst Biosciences Inc | polipeptídeos de fator x modificados e uso dos mesmos |
| US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
| US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
| WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2799316B2 (ja) * | 1987-06-12 | 1998-09-17 | ヘキスト・マリオン・ルセル株式会社 | 雑種ヒトプロテインｃおよびその遺伝子工学的製法 |
| JPH0246296A (ja) * | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| JP3330932B2 (ja) * | 1990-01-29 | 2002-10-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 抗凝固剤タンパク質 |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
-
1997
- 1997-10-23 US US08/955,636 patent/US6017882A/en not_active Expired - Lifetime
-
1998
- 1998-10-20 CA CA002307175A patent/CA2307175C/en not_active Expired - Fee Related
- 1998-10-20 JP JP2000517087A patent/JP4276379B2/ja not_active Expired - Fee Related
- 1998-10-20 PT PT98967009T patent/PT1090128E/pt unknown
- 1998-10-20 NZ NZ504114A patent/NZ504114A/xx unknown
- 1998-10-20 ES ES05026205.4T patent/ES2496104T3/es not_active Expired - Lifetime
- 1998-10-20 IL IL13560398A patent/IL135603A0/xx unknown
- 1998-10-20 TW TW087117304A patent/TW587081B/zh active
- 1998-10-20 BR BR9814611-4A patent/BR9814611A/pt active Search and Examination
- 1998-10-20 ID IDW20000983A patent/ID26330A/id unknown
- 1998-10-20 WO PCT/US1998/022152 patent/WO1999020767A1/en not_active Ceased
- 1998-10-20 HR HR20000234A patent/HRP20000234A2/hr not_active Application Discontinuation
- 1998-10-20 SG SG200203078A patent/SG105547A1/en unknown
- 1998-10-20 KR KR1020007004378A patent/KR20010031370A/ko not_active Ceased
- 1998-10-20 HU HU0102257A patent/HU225993B1/hu not_active IP Right Cessation
- 1998-10-20 DK DK98967009T patent/DK1090128T3/da active
- 1998-10-20 EA EA200000449A patent/EA200000449A1/ru unknown
- 1998-10-20 DE DE69839313T patent/DE69839313T2/de not_active Expired - Lifetime
- 1998-10-20 PL PL98340284A patent/PL194194B1/pl unknown
- 1998-10-20 AP APAP/P/2000/001811A patent/AP2000001811A0/en unknown
- 1998-10-20 CN CNB988125811A patent/CN1246462C/zh not_active Expired - Fee Related
- 1998-10-20 TR TR2000/01105T patent/TR200001105T2/xx unknown
- 1998-10-20 ES ES98967009T patent/ES2303362T3/es not_active Expired - Lifetime
- 1998-10-20 AT AT98967009T patent/ATE390486T1/de active
- 1998-10-20 EP EP05026205.4A patent/EP1676919B1/en not_active Expired - Lifetime
- 1998-10-20 AU AU27024/99A patent/AU749279C/en not_active Ceased
- 1998-10-20 EP EP98967009A patent/EP1090128B1/en not_active Expired - Lifetime
- 1998-10-21 ZA ZA989597A patent/ZA989597B/xx unknown
- 1998-10-22 AR ARP980105278A patent/AR020048A1/es unknown
- 1998-10-22 MY MYPI98004808A patent/MY136336A/en unknown
-
2000
- 2000-04-14 IS IS5449A patent/IS5449A/is unknown
- 2000-04-18 NO NO20002025A patent/NO20002025L/no not_active Application Discontinuation
-
2002
- 2002-03-20 AR ARP020101003A patent/AR035786A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035786A2 (es) | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen | |
| JP2001520042A5 (es) | ||
| Sadler | Thrombomodulin structure and function | |
| ATE404583T1 (de) | Funktionelle antagonisten von hedgehog-aktivität | |
| KR870002848A (ko) | 항응고물질, 그 제조방법 및 이물질을 유효 성분으로 포함하는 항응고제 | |
| ATE342962T1 (de) | Zusammensetzungen und verfahren für verbesserte zellkultur | |
| PT1003560E (pt) | Radioprotector para peptidos marcados com radioisotopos | |
| MXPA03002218A (es) | Peptidos antimicrobianos y metodos de uso. | |
| BRPI0014076B8 (pt) | benzamidas e inibidores correlatos do fator xa | |
| ATE506071T1 (de) | Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa) | |
| AR000862A1 (es) | Variantes de una ó-amilasa madre, un metodo para producir la misma, una estructura de adn y un vector de expresion, una celula transformada por dichaestructura de adn y vector, un aditivo para detergente, composicion detergente, una composicion para lavado de ropa y una composicion para la eliminacion del | |
| DE60144145D1 (de) | Subtilisin-variante | |
| EP1548032A4 (en) | KDR-PEPTIDES AND VACCINES CONTAINING THEM | |
| BR0108959A (pt) | Composições de poloxmero ou poloxamina melhoradas para distribuição de ácido nucléico | |
| ES2094111T3 (es) | Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen. | |
| TR200002179T2 (tr) | Kristalin teriparatid. | |
| DE3484616D1 (de) | Enzymwiderstandsfaehige immunomodulatorische peptide. | |
| Xiao et al. | Phosphorylation of HMG‐I by Protein Kinase C Attenuates Its Binding Affinity to the Promoter Regions of Protein Kinase C γ and Neurogranin/RC3 Genes | |
| WO2003012050A3 (en) | Mitochondrial genome replenishment | |
| Bab et al. | Isolation of mitogenically active C‐terminal truncated pentapeptide of osteogenic growth peptide from human plasma and culture medium of murine osteoblastic cells | |
| ATE426028T1 (de) | Zellvolumenregulierte humane kinase h-sgk | |
| AR042968A1 (es) | Anticuerpos de virus anti-dengue composiciones metodos y usos | |
| Sánchez et al. | Isolation and characterization of two disintegrins inhibiting ADP-induced human platelet aggregation from the venom of Crotalus scutulatus scutulatus (Mohave Rattlesnake) | |
| DK1276763T3 (da) | Anti-fryseproteiner, deres fremstilling og anvendelse | |
| BR0009396A (pt) | Lipase, composição detergente, sequência de dna, vetor de expressão, célula hospedeira transformada, e, processo para produzir a lipase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |